Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002635 · ClinicalTrials.gov registry record · Phase 2
Aminocamptothecin in Treating Patients With T-cell Lymphoma
A Phase 2 study of Lymphoma, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT00002635: Completed Phase 2 study of Lymphoma, sponsored by Yale University.
NCT00002635 is a Phase 2 study of Lymphoma that has completed, run by Yale University. The registered enrollment target is 12 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002635, a Phase 2 study of Lymphoma, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL filgrastim
- DRUG aminocamptothecin
Study Locations (3)
Connecticut
- Yale Comprehensive Cancer Center - New Haven
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Massachusetts
- New England Medical Center Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1995-05 |
| Est. Completion | 2000-04 |
| Phase | Phase 2 |
What the finished NCT00002635 record still lists
NCT00002635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which filgrastim is the first listed.
NCT00002635 reports a single indexed study location in Connecticut, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00002635 about?
NCT00002635 is a clinical study titled "Aminocamptothecin in Treating Patients With T-cell Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.
What is the current status of trial NCT00002635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 1995-05. Estimated completion is 2000-04.
What conditions does trial NCT00002635 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00002635?
The interventions under investigation include: filgrastim (BIOLOGICAL), aminocamptothecin (DRUG).
Who is sponsoring clinical trial NCT00002635?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002635 being conducted?
This trial has 3 study locations across Connecticut, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002635's enrollment target sits among peer trials
12 269th of 299 higher than 28 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia